Cardiometabolic
From Patients to Customers: GLP-1 Marketing Is Rewriting Obesity Care
GLP-1 medicines were initially positioned around diabetes and chronic obesity management. Their commercial language is now moving closer to weight loss, lifestyle and consumer wellness. That shift could broaden demand, but it also creates a growing tension between medical indications, public-health guidance and direct-to-consumer marketing.
Dementia prevention has a cardiometabolic blind spot
New nicotine products could become the next major cardiovascular policy failure
Childhood obesity is the next cardiometabolic crisis already unfolding
BMI is not enough. Cardiometabolic risk is hiding in where fat lives
Resistant hypertension may need a diagnostic revolution, not just another drug
When diabetes tech fails, personalised care fails with it
Type 1 diabetes has a kidney problem. FDA is now fast-tracking a possible answer.
Triglycerides are back in the spotlight. Europe is reviewing Sobi’s olezarsen for severe risk.
MASH, a serious fatty liver disease, is becoming a cardiometabolic condition
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Cardiometabolic
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases